We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Expression Patterns Identified Associated with Multiple Sclerosis

By Biotechdaily staff writers
Posted on 07 Nov 2007
Gene expression patterns have been identified in white blood cells (WBCs) that are statistically associated with multiple sclerosis (MS), a disease of the central nervous system (CNS). More...
Genomic analysis also identified gene patterns associated with two recently approved therapies for MS.

MS is a chronic inflammatory disease that selectively destroys the myelin sheaths of neurons within the CNS, leading to loss of neurological function with unpredictable course and severity. The disease affects approximately 350,000 persons in the United States alone, and more than 25,000 new diagnoses are confirmed each year. Susceptibility to MS is determined by genetic and environmental factors that are not well understood, requiring a battery of expensive and in many cases invasive tests to arrive at a diagnosis.

Gene Logic (Gaithersburg, MD, USA) scientists evaluated the WBC samples using gene expression microarrays that enable comprehensive analysis of the human genome. They compared untreated MS samples with non-MS samples (both non-diseased and from other autoimmune diseases), as well as MS samples before and after treatment with Avonex (beta-interferon) and Copaxone (glatiramer acetate). Statistically significant gene expression differences between the groups were determined to identify gene sets.

"These studies lay the foundation for several MS diagnostics that could have significant clinical applications,” said Larry Tiffany, senior vice president and general manager of Genomics at Gene Logic. "A blood-based test that can definitively diagnose MS would clearly be of high value to physicians. A ‘rule-out' test demonstrating that a patient does not have MS would also be clinically useful, since it eliminates a lengthy, costly and often invasive medical work-up in many patients with symptoms similar to MS. Other potential applications of our comprehensive approach could be tests to monitor disease activity, identify sub-types of MS, and functionally assess drug activity.”

Gene Logic is using blood samples from the repository of the Accelerated Cure Project for Multiple Sclerosis (ACP), a non-profit organization that has assembled the largest multi-disciplinary bio-bank for MS research.


Related Links:
Gene Logic
Cure Project for Multiple Sclerosis

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.